AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.71 |
Market Cap | 224.67M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.85 |
PE Ratio (ttm) | -1.71 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.69 |
Volume | 547,624 |
Avg. Volume (20D) | 892,793 |
Open | 4.83 |
Previous Close | 4.76 |
Day's Range | 4.80 - 5.08 |
52-Week Range | 4.67 - 36.25 |
Beta | undefined |
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...
Analyst Forecast
According to 11 analyst ratings, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $39.5, which is an increase of 712.76% from the latest price.
Next Earnings Release
Analysts project revenue of $2.20M, reflecting a -13.04K% YoY shrinking and earnings per share of -0.83, making a 7.79% increase YoY.